| Literature DB >> 32968279 |
Daichao Xu1,2, Heng Zhao1, Minzhi Jin1, Hong Zhu1, Bing Shan2, Jiefei Geng1, Slawomir A Dziedzic1, Palak Amin1, Lauren Mifflin1, Masanori Gomi Naito1, Ayaz Najafov1, Jing Xing3, Lingjie Yan2, Jianping Liu4, Ying Qin2, Xinqian Hu1, Huibing Wang1, Mengmeng Zhang2, Vica Jean Manuel1, Li Tan2, Zhuohao He2,5, Zhenyu J Sun6, Virginia M Y Lee5, Gerhard Wagner7, Junying Yuan8.
Abstract
Cell death in human diseases is often a consequence of disrupted cellular homeostasis. If cell death is prevented without restoring cellular homeostasis, it may lead to a persistent dysfunctional and pathological state. Although mechanisms of cell death have been thoroughly investigated1-3, it remains unclear how homeostasis can be restored after inhibition of cell death. Here we identify TRADD4-6, an adaptor protein, as a direct regulator of both cellular homeostasis and apoptosis. TRADD modulates cellular homeostasis by inhibiting K63-linked ubiquitination of beclin 1 mediated by TRAF2, cIAP1 and cIAP2, thereby reducing autophagy. TRADD deficiency inhibits RIPK1-dependent extrinsic apoptosis and proteasomal stress-induced intrinsic apoptosis. We also show that the small molecules ICCB-19 and Apt-1 bind to a pocket on the N-terminal TRAF2-binding domain of TRADD (TRADD-N), which interacts with the C-terminal domain (TRADD-C) and TRAF2 to modulate the ubiquitination of RIPK1 and beclin 1. Inhibition of TRADD by ICCB-19 or Apt-1 blocks apoptosis and restores cellular homeostasis by activating autophagy in cells with accumulated mutant tau, α-synuclein, or huntingtin. Treatment with Apt-1 restored proteostasis and inhibited cell death in a mouse model of proteinopathy induced by mutant tau(P301S). We conclude that pharmacological targeting of TRADD may represent a promising strategy for inhibiting cell death and restoring homeostasis to treat human diseases.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32968279 DOI: 10.1038/s41586-020-2757-z
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962